

to the urgent need to proceed with the meeting as scheduled in order to address these issues in a timely manner.

Dated: August 30, 1996.

Margery G. Grubb,

*Senior Committee Management Specialist,
NIH.*

[FR Doc. 96-22996 Filed 9-9-96; 8:45 am]

BILLING CODE 4140-01-M

Genetic Testing Task Force; Notice of Meeting

Notice is hereby given of the fourth meeting of the Task Force on Genetic Testing of the National Institutes of Health-Department of Energy Joint Working Group on the Ethical, Legal, and Social Implications of Human Genome Research (ELSI Working Group) on Tuesday, September 24, 1996, 1:00 pm to recess; Wednesday, September 25, 1996, 7:30 am to adjournment, at the Clarion Hotel at Mount Vernon Square, 612 Cathedral Street, Baltimore, Maryland, (410) 727-7101.

CONTACT PERSON: Neil Holtzman, M.D., M.P.H., Genetics and Public Policy Studies, The Johns Hopkins Medical Institutions, 550 North Broadway, Suite 511, Baltimore, Maryland 21205, (410) 955-7894.

The Task Force has developed Interim Principles primarily regarding scientific validation of new tests; laboratory quality; and education, counseling, and delivery. At this meeting, the Task Force will continue its consideration of recommendations to implement the Interim Principles, as well as revisions to the Interim Principles. The Interim Principles are available on the World Wide Web at: <http://infonet.welch.jhu.edu/policy/genetics/>

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Dr. Holtzman in advance of the meeting.

Dated: September 4, 1996.

Margery G. Grubb,

*Senior Committee Management Specialist,
NIH.*

[FR Doc. 96-23012 Filed 9-9-96; 8:45 am]

BILLING CODE 4140-01-M

Notice of Meeting

Notice is hereby given of the open, public hearing of the National Institutes of Health-Department of Energy Joint Working Group on the Ethical, Legal, and Social Implications of Human Genome Research (ELSI Working Group) Evaluation Committee, on Wednesday, October 23, 1996, 9:00 am to noon at

Hotel Sofitel Chicago, 5550 N. River Road, Rosemont, Illinois 60018-5194; TEL: (847) 678-4488.

Contact Person: Bettie Graham, Ph.D., NIH/NCHGR Bldg. 38A, Rm. 614, Bethesda, MD 20892; (301) 496-7531.

The ELSI Working Group Evaluation Committee has been charged with evaluation of the ELSO activities and role of external advisors in the ELSO program. The Committee will assess how, in the near term, it would be best to structure input on ELSI issues raised by and as a consequence of the Human Genome Project. The Committee will also assess how, in the longer term, it would be best to structure input on ELSI issues raised more generally by research involving human genetics. The Committee is seeking public comments on the following questions:

1. What role should external advisors (currently the ELSI Working Group) play in the ELSI program?
2. How should the external ELSI advisors relate to other government and private groups studying these issues?
3. How should the external ELSI advisors relate to other institutes, programs, and entities at the National Institutes of Health (NIH) and Department of Energy (DOE) with a shared research interest?
4. To whom at the NIH and the DOE should the external advisors report?
5. What procedures should be established for appointment of members, priority setting, budget, staffing, and policy development?
6. What changes, if any, will be necessary in the ELSI program as the focus of research shifts away from genomics?

Individuals or representatives of organizations wishing to make an oral presentation, of no more than five minutes, to the ELSI Working Group Evaluation Committee, on Wednesday, October 23, should submit their name, affiliation, address, telephone number, and summary of their remarks to Dr. Graham at the above address by October 14. Those making oral comments to the Committee will be accommodated to the extent possible during the time allotted for oral public comments. Written comments will be accepted up to October 14.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Dr. Graham two weeks in advance of the meeting.

Individuals who are unable to attend the public meeting, but who would like to submit comments may do so by

writing to Mark A. Rothstein, Co-Chair, ELSI Working Group Evaluation Committee, Health Law and Policy Institute, University of Houston, Houston, TX 77204-6381 or to the Committee by e-mail at: elsiwg@net.bio.net.

Dated: September 4, 1996.

Margery G. Grubb,

*Senior Committee Management Specialist,
NIH.*

[FR Doc. 96-23008 Filed 9-9-96; 8:45 am]

BILLING CODE 4140-01-M

Notice of Meeting of the National Bioethics Advisory Commission (NBAC)

SUMMARY: Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), this notice is hereby given to announce an open meeting of the National Bioethics Advisory Commission (NBAC). The purpose of the meeting is to address: (i) the protections of the rights and welfare of human research subjects and (ii) the management and use of genetic information.

DATES: October 4, 1996, 8:30 a.m.-4:30 p.m.

PLACE: Conference Room 10, Building 31, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892.

SUPPLEMENTARY INFORMATION: The President established the National Bioethics Advisory Commission (NBAC) by Executive Order 12975, October 3, 1995. The purpose of the NBAC is to provide advice and make recommendations to the National Science and Technology Council, and other appropriate entities on bioethical issues arising from research on human biology and behavior and the applications, including the clinical applications, of that research.

Tentative Agenda

Friday, October 4, 1995

- 8:30 a.m. Call to order, opening remarks, and introductions
- 8:45 a.m. Presentations by spokespersons for members of the U.S. Senate and U.S. House of Representatives and discussion with and among NBAC members
- 10:30 a.m. Break
- 10:50 a.m. Morning presentations and discussions continue
- 11:45 a.m. Lunch
- 1:00 p.m. Presentations by Administration spokespersons and discussion with and among NBAC members

2:30 p.m. Break
 2:50 p.m. Afternoon presentations and discussions continue
 3:20 p.m. Public comment
 4:20 p.m. NBAC members and staff discussion
 4:30 p.m. Adjourn

Public Participation

The meeting is open to the public with attendance limited to space available. Members of the public who wish to make oral statements should contact NBAC at the address or telephone number listed below at least seven business days prior to the meeting. Reasonable provisions will be made to include on the agenda presentations by persons requesting an opportunity to speak. Individuals who plan to attend the meeting and need special assistance, such as sign language interpretation or other special accommodations should also contact NBAC at the address or telephone number listed below at least seven business days prior to the meeting. Persons who wish to file written statements with NBAC may do so at any time.

FOR FURTHER INFORMATION CONTACT:

Patricia Norris, Communications Director, National Bioethics Advisory Commission, MSC-7508, 6100 Executive Boulevard, Suite 3C01, Rockville, Maryland 20892-7508, telephone 301-402-4242, fax nos. 301-480-6900 or 301-402-2071.

Dated: September 3, 1996.

Margery G. Grubb,
Senior Committee Management Specialist,
NIH.

[FR Doc. 96-23006 Filed 9-9-96; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute; Notice of Meeting

Notice is hereby given of the meeting of the National Cancer Institute Board of Scientific Advisors Prevention Program Working Group, September 17, 1996 at the Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, Maryland.

The meeting will be open to the public on September 17, 1996 from 8:00 a.m. to 8:30 a.m. for general introductory remarks and announcements relating to the Institute's Prevention Programs.

The meeting will be closed to the public on September 17, 1996 from 8:30 a.m. to adjournment for discussion of confidential issues relating to the review, discussion and evaluation of individual programs and projects conducted by the NCI Prevention

Program. These discussions will reveal confidential trade secrets or commercial property such as patentable material, and personal information including consideration of personnel qualifications and performance, the competence of individual investigators and similar matters, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Information pertaining to the meeting may be obtained from Dr. Jack Gruber, Executive Secretary, National Cancer Institute Prevention Program Working Group, National Cancer Institute, 6130 Executive Blvd., EPN, Rm. 540, Bethesda, MD 20892, (301-496-9740). Individuals who plan to attend and need special assistance such as sign language interpretation or other reasonable accommodations should contact Dr. Jack Gruber in advance of the meeting.

Dated: August 30, 1996.

Susan K. Feldman,
Committee Management Officer, NIH.
 [FR Doc. 96-23000 Filed 9-9-96; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute; Notice of Meeting

Notice is hereby given of the meeting of the National Cancer Institute Board of Scientific Advisors Clinical Trials Working Group, September 16-17, 1996 at the Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, Maryland.

This meeting will be open to the public on September 16, 1996 from 8:00 am to 8:30 am for introductory remarks and discussion of the Institutes Clinical Trails Extramural Program and September 17, 1996 from 8:00 am to 2:00 pm to discuss priority setting in clinical trials.

The meeting will be closed to the public on September 16, 1996 from 8:30 am to recess and on September 17, 1996 from 2:00 pm to adjournment for discussion of confidential issues relating to the review, discussion and evaluation of individual programs and projects conducted by the Clinical Trials Extramural Program. These discussions will reveal confidential trade secrets or commercial property such as patentable material, and personal information including consideration of personnel qualifications and performance, the competence of individual investigators and similar matters, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Information pertaining to the meeting may be obtained from Dr. John Cole, III, Executive Secretary, National Cancer Institute Clinical Trials Working Group, National Cancer Institute, 6130 Executive Blvd., EPN, Rm. 540, Bethesda, MD 20892, (301-496-1718). Individuals who plan to attend and need special assistance such as sign language interpretation or other reasonable accommodations should contact Dr. John Cole, III in advance of the meeting.

Dated: August 30, 1996.

Susan K. Feldman,
Committee Management Officer, NIH.
 [FR Doc. 96-23003 Filed 9-9-96; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute; Notice of Meeting

Pursuant to Public Law 92-463, notice is hereby given of a meeting of the President's Cancer Panel.

This meeting will be open to the public as indicated below, with attendance by the public limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below.

This meeting will be closed in accordance with the provisions set forth in sec. 552b(c)(9), Title 5, U.S.C. for discussion of future meetings and preparation of the annual report to the President. These discussions could disclose information, the premature disclosure of which would be likely to significantly frustrate implementation of proposed action the Panel may plan to take.

Carole Frank, the Committee Management Officer, National Cancer Institute, Executive Plaza North, Room 630M, 6130 Executive Blvd., MSC 7405, Bethesda, MD 20892-7405 (301/496-5708) will provide a summary of the meeting and the roster of committee members upon request. Other information pertaining to the meetings may be obtained from the contact person indicated below.

Committee Name: President's Cancer Panel.

Dated: September 23-24, 1996.

Place: Henry B. Gonzalez Convention Center, 200 East Market, San Antonio, TX 78205.

Closed: September 23, 1996-7:00 p.m. to 9:00 p.m.

Agenda: Planning session to discuss future meetings and preparation of the mandatory annual report of the Chairman to the President.